$OCUL News

Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?

Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day - Slideshow

Why Ocular Therapeutix (OCUL) Stock Is Up Today

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028

Ocular Therapeutix Appoints Jason Robins CFO, Effective June 10

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026